Clinical Trial

Olverembatinib for FGFR1-rearranged Neoplasms

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 30, 2022 (before its estimated August 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
FGFR1-rearranged myeloid/lymphoid neoplasms are a rare hematologic malignancy with very poor outcome despite intensive chemotherapy. The only curative option is thought to be allogeneic hematopoietic stem cell transplantation (HSCT) in remission. This phase II study is aimed to evaluate the efficacy of Olverembatinib, consolidated with HSCT in the treatment of FGFR1-rearranged myeloid/lymphoid neoplasm.
Trial Details
NCT Number NCT05521204
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions Myeloproliferative Neoplasm, Acute Leukemia
Enrollment 20 participants
Start Date 2022-09-01
Primary Completion 2024-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2022-08-30